This case, described as the last big merger in the global beer industry, involves a valuation of the merged company using a basic discounted cash flow (DCF) methodology. Students are asked to calculate and compare the value of the merged entity with the standalone valuations of the respective companies to see if there is indeed value in merging. An additional consideration is the impact of a large net cash position on the company's stock price when growth stalls.

The case describes the lead-up to the offer to acquire Baxalta Inc by Shire PLC in the summer of 2015, weeks after Baxalta was spun out of Baxter's BioScience business. The setting is the biopharmaceutical sector - the fastest-growing in the global pharmaceutical industry in 2014, when M&As reached a record $219.4 billion. Shire, a leader in the treatment of rare diseases whose share price had quadrupled since 2010, had sustained strong sales growth. Baxalta was specialised in haematology, immunology and oncology, with product sales of $6 billion in 2014. After a private proposal to Baxalta's management in July 2015 was rebuffed, Shire considered making a public tender offer at $45.23 per share in August, valuing Baxalta at $30.6 billion. It estimated annual cost synergies to be $500 million, with additional tax and revenue synergies. The case puts students in the shoes of Shire's senior management as they decide whether to pursue the acquisition on the terms envisaged. Instructors can obtain a discounted cash flow (DCF) Excel template (for an in-class valuation exercise) as well as the model solutions on request from [email protected]

The case focuses on blockchain (and distributed ledger technology or DLT) - a 'hot' area of fintech - and on R3 as a fintech consortium that includes some of the world's largest banks, financial institutions and regulators. R3 started out as a family office in 2014 and evolved into a fintech company focused on the application of distributed ledger technology (DLT). Within three short years it had built a global consortium of 80 members from the financial services industry, including Barclays, J.P. Morgan, Commonwealth Bank of Australia and UBS. The consortium's efforts resulted in an open-source DLT called Corda, geared towards handling increasingly complex transactions and regulatory oversight. Although Corda was inspired by blockchain, R3 did not view it as a blockchain product. In May 2017, R3's Series A raised US$107 million in funding to continue the development and implementation of Corda and expand its Lab & Research Center. Barely a year later, speculation arose that R3 was exploring an IPO.